NAVB - Navidea Biopharmaceuticals, Inc

NYSE American - Nasdaq Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/201512/31/2014
Total Revenue1,810.4374,971.6343,013.3612,054.096
Cost of Revenue3.65162.263.2262.626
Gross Profit1,806.7864,909.3743,010.1352,051.47
Operating Expenses
Research Development4,513.8427,138.0810,562.72915,116.978
Selling General and Administrative10,552.0717,920.03610,888.1469,525.984
Non Recurring----
Others----
Total Operating Expenses15,069.56415,120.37621,454.10124,645.588
Operating Income or Loss-13,259.127-10,148.742-18,440.74-22,591.492
Income from Continuing Operations
Total Other Income/Expenses Net-4,530.5592,770.848-4,603.857-7,767.376
Earnings Before Interest and Taxes-13,259.127-10,148.742-18,440.74-22,591.492
Interest Expense-159.029-4.866-1,269.916-3,363.731
Income Before Tax-17,789.686-7,377.894-23,044.597-30,358.868
Income Tax Expense-4,062.489---
Minority Interest668.7468.91469.558469.558
Net Income From Continuing Ops-13,727.197-7,377.894-23,044.597-30,358.868
Non-recurring Events
Discontinued Operations88,673.053-6,931.137-4,518.938-5,367.801
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income74,946.066-14,308.383-27,562.68-35,726.669
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares74,946.066-14,308.383-27,608.68-35,726.669